PURPOSE To assess the safety of a recombinant adeno-associated viral vector expressing REP1 (rAAV2.REP1) in choroideremia subjects. METHODS Design: Phase I clinical trial. PARTICIPANTS Six adult male subjects, 30-42 years of age, with genetically confirmed choroideremia (CHM) were enrolled. The e…